Catapult BioAccel announces funding of Kemeta

NewsGuard 100/100 Score

Catapult BioAccel, formerly named CatapultBio, has announced the funding of an Arizona-based early stage firm, Kemeta LLC, a company developing a revolutionary product for application in consumer health and medical markets.

“We awarded funding to Kemeta based on its innovative technology, market potential and the past success of its CEO,” said MaryAnn Guerra, CEO and board chairman of Catapult BioAccel, an Arizona-based nonprofit organization established this year to accelerate new scientific ideas, transferring them into commercial products and viable business ventures.

Kemeta, based in Mesa, Ariz., is developing a palm-size breath acetone analyzer that measures fat metabolism in a single breath. Acetone is the known breath biomarker for fat metabolism. Catapult BioAccel is funding a portion of the activities that will advance the product development with a $200,000 grant from its New Venture Development Program (NVDP). This validation process is a key step on the path to commercialization and involves several clinical studies specific to fat metabolism. Kemeta is collaborating with another Arizona company, Kronos Science Laboratories, to perform the clinical studies over the next several months.

“The funding from Catapult BioAccel is pivotal for us in terms of obtaining the data necessary to validate product-use claims in advance of submittal to the FDA for approval, a critical stage in the commercialization process,” said Dr. Joan Vrtis, CEO, president and founder of Kemeta.

Vrtis estimates Kemeta’s first product could be available to healthcare professionals and consumers in 2010.

While there are billions of dollars available for basic research, relatively little funding is accessible for the commercialization activities required to make new technologies more alluring for venture capitalists and other investors. With the grant, Catapult BioAccel fills one of two funding gaps for Kemeta that could prevent the commercialization of its technology.


Catapult BioAccel


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Gut bacteria play a pivotal role in obesity's impact on body fat metabolism